Eligibility for the medical therapy among men with non‐obstructive azoospermia—Findings from a multi‐centric cross‐sectional study

Edoardo Pozzi,Greeshma Venigalla,Adele Raymo,Vishal Ila,Arnold P. P. Achermann,Sandro C. Esteves,Andrea Salonia,Ranjith Ramasamy
DOI: https://doi.org/10.1111/andr.13670
2024-05-30
Andrology
Abstract:Background Existing literature does not provide accurate epidemiological data regarding the true prevalence of men with non‐obstructive azoospermia (NOA) who would be eligible for hormonal optimization therapy, according to specific pre‐treatment criteria. Objectives To investigate the characteristics of those men with NOA who would qualify for the medical therapy prior to any SR procedure in a large multi‐centric cross‐sectional study. Materials and methods Complete data from 1644 NOA patients seeking medical help for primary infertility at three tertiary referral centers from USA, Brazil, and Italy were analyzed. Baseline serum hormone levels were collected for all patients. NOA was confirmed after two consecutive semen analyses. Genetic tests, including karyotype analysis and Y microdeletions, were performed on all patients. Patients with secondary hypogonadism (total testosterone (T) levels less than 300 ng/dL and luteinizing hormone (LH) levels less than 8 mIU/mL) were earmarked as potential candidates for receiving clomiphene citrate (CC) and/or human chorionic gonadotropin (hCG). Patients with a T to 17β‐estradiol (E2) ratio
andrology
What problem does this paper attempt to address?